Next Article in Journal
Co-Occurrence of mcr-1 and Carbapenem Resistance in Avian Pathogenic E. coli Serogroup O78 ST95 from Colibacillosis-Infected Broiler Chickens
Previous Article in Journal
Evaluation of Dosing Guidelines for Gentamicin in Neonates and Children
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Antibiotics
Volume 12
Issue 5
10.3390/antibiotics12050811
Review Report
antibiotics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Article
Peer-Review Record

Safety Profile of Medicines Used for the Treatment of Drug-Resistant Tuberculosis: A Descriptive Study Based on the WHO Database (VigiBase®)

Antibiotics 2023, 12(5), 811; https://doi.org/10.3390/antibiotics12050811
by Alemayehu Lelisa Duga 1,2,3,*, Francesco Salvo 1, Alexander Kay 3,4 and Albert Figueras 1
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Antibiotics 2023, 12(5), 811; https://doi.org/10.3390/antibiotics12050811
Submission received: 10 March 2023 / Revised: 19 April 2023 / Accepted: 22 April 2023 / Published: 25 April 2023

Round 1

Reviewer 1 Report

The paper aimed to describe the magnitude and characteristics of DR-TB 16 related ADRs through analysis of ADRs reported to the WHO database in the period of January 2018 to December 2020; and found that A high proportion of the medicines responsible for frequent ADRs are the backbone of the shorter DR-TB treatment regimen currently in use. The authors understand the limitation of the study. The paper could provide interesting information to audience. The manuscript needs more proofreading. The following comments aim to improve the manuscript.

 

Minor:

1.      In Table 1, how did the authors determine the Seriousness of ADR, please describe it at the table legend?

1.      Please correct “fol-lowed by ethionamide” (line 23)

2.      Please correct “fre-quent ADRs are the” (line 27)

3.      “medicines used in patients with DR TB is” acronym is not consistent some are written as “DR-TB” (line 72)

4.      Please modify “Out the 25 different medicines” (line 90)

Author Response

Please see the attachment

Author Response File: Author Response.pdf

Reviewer 2 Report

Research Manuscript Title: Safety profile of medicines used for the treatment of Drug resistance Tuberculosis: A descriptive study based on the WHO database(VigiBase®)

Manuscript ID: Antibiotics-2306343

The purpose of this study was aimed at describing the magnitude and characteristics of DR-TB related ADRs through analysis of ADRs reported to the WHO database (VigiBase® ) in the period of January 2018 to December 2020.

Major comments

There are some issues which need to be addressed by the authors:

Comment #1: In this study, how many patients received bedaquiline and delamanid concomitantly ? Were there any fatal drug-related adverse events arising out of sudden cardiac death(SCD) that occurred among patients ? How many patients were pregnant while receiving antitubercular treatment & what were the outcomes ?

Comment #2: The “Data Search Criteria” can preferably be arranged in a tabular form.

Comment #3: English language needs major touching up. Many sentences are confusing, do not lead to scientific meaning.

Author Response

Please see the attachment 

Author Response File: Author Response.pdf

Round 2

Reviewer 2 Report

All comments have been addressed.

Back to TopTop